1. Academic Validation
  2. Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non-Small Cell Lung Cancer from Tuberculosis

Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non-Small Cell Lung Cancer from Tuberculosis

  • Lab Med. 2022 Sep 15;lmac085. doi: 10.1093/labmed/lmac085.
Wenqiang Zheng 1 Bin Quan 2 Guangjian Gao 1 Puhong Zhang 3 Lizhu Huang 4
Affiliations

Affiliations

  • 1 Department of Nuclear Medicine, First Affiliated Hospital of Wannan Medical College, Wuhu, China.
  • 2 Department of Infectious Diseases, First Affiliated Hospital of Wannan Medical College, Wuhu, China.
  • 3 Department of Clinical Laboratory, Second Affiliated Hospital of Wannan Medical College, Wuhu, China.
  • 4 Department of Clinical Laboratory, First Affiliated Hospital of Wannan Medical College, Wuhu, China.
Abstract

Objective: Non-small cell lung Cancer (NSCLC) holds high metabolic tumor burden and circulating cell-free DNA (cfDNA) levels, and the relationship between metabolic tumor burden and cfDNA in NSCLC and the underlying mechanism of their interaction therein remain poorly characterized. Our aim was to evaluate the clinical value of cfDNA and metabolic tumor burden by positron emission tomography-computed tomography (PET/CT) for NSCLC differential diagnosis from tuberculosis in patients with solitary pulmonary nodules.

Methods: Metabolic tumor burden values in humans (subjects with NSCLC, subjects with tuberculosis, and healthy control subjects) and relevant mouse models were detected by preoperative 18F-fluorodeoxyglucose PET (18F-FDG PET/CT) and [3H]-2-deoxy-DG uptake, respectively. The cfDNA levels were detected by quantifying serum cfDNA fragments from the ALU (115 bp) gene using reverse transcription-polymerase chain reaction. RNA sequence was performed to determine the underlying target genes and knocked down or inhibited the target genes in vivo and in vitro to determine the mechanism therein.

Results: Metabolic tumor burden correlated with serum cfDNA levels in NSCLC subjects but not in tuberculosis subjects or healthy controls. Mouse models showed a similar phenomenon. In addition, the RNA sequence showed that glucose transporter 1 (GLU1), factor-related Apoptosis ligand (FasL), Caspase 8, and Caspase 3 were significantly increased in NSCLC mouse tumors compared with those in tuberculosis mouse masses. Inhibiting the metabolic tumor burden by blocking or knocking down GLU1 markedly reduced the expression of FasL, the phosphorylation of Caspase 8/Caspase 3, and serum cfDNA levels/Apoptosis percentage in vivo and in vitro. Furthermore, the use of a combination of cfDNA and metabolic tumor burden allowed better ability to distinguish NSCLC subjects from those with tuberculosis or healthy controls than either method used alone.

Conclusion: Metabolic tumor burden promotes the formation of circulating cfDNA through GLU1-mediated Apoptosis in NSCLC, and the combination of cfDNA and metabolic tumor burden could be valuable for distinguishing NSCLC from tuberculosis.

Keywords

circulating cell-free DNA; glucose transporter 1; metabolic tumor burden; non–small cell lung cancer; tuberculosis.

Figures
Products